Abstract
BackgroundSeveral studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 study of pembrolizumab monotherapy for previously treated recurrent...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have